Treats HIV-1 infection. ANDA 91677, held by Hetero Labs Ltd Iii. Lopinavir; Ritonavir.
As of Nov 21, 2026, ANDA 91677 (Lopinavir and Ritonavir), held by Hetero Labs Ltd Iii, was first approved by FDA on Jun 4, 2021, with 0 approved supplements and 0 published complete response letters.
Lopinavir and ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 14 days and older. Limitations of Use:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 4, 2021 | Original application | Approved |
| Lopinavir and Ritonavir100MG;25MG · tablet;oral | Lopinavir; Ritonavir | Rx |
| Lopinavir and Ritonavir200MG;50MG · tablet;oral | Lopinavir; Ritonavir | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters